Barinthus Biotherapeutics (NASDAQ:BRNS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a report published on Thursday morning, Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

A number of other equities research analysts also recently weighed in on BRNS. Barclays dropped their price target on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating for the company in a research note on Thursday, June 13th. William Blair reissued an outperform rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Finally, Alliance Global Partners dropped their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a buy rating on the stock in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Performance

NASDAQ:BRNS opened at $1.18 on Thursday. The company has a market capitalization of $46.06 million, a price-to-earnings ratio of -0.64 and a beta of -0.53. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10. The company has a 50-day moving average of $1.31 and a 200-day moving average of $1.86.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). Sell-side analysts forecast that Barinthus Biotherapeutics will post -1.71 EPS for the current year.

Institutional Trading of Barinthus Biotherapeutics

A number of hedge funds have recently modified their holdings of BRNS. Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics in the second quarter worth $2,119,000. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics in the second quarter valued at about $25,000. Ipswich Investment Management Co. Inc. acquired a new position in shares of Barinthus Biotherapeutics during the second quarter worth $32,000. M&G Plc acquired a new position in shares of Barinthus Biotherapeutics in the second quarter worth approximately $7,276,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Barinthus Biotherapeutics in the 1st quarter worth approximately $1,292,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.